CN1235544A - 盐酸[R－(Z)]－α－甲氧亚氨基－α－(1－氮杂双环[2.2.2]辛－3－基)乙腈控释剂型 - Google Patents

盐酸[R－(Z)]－α－甲氧亚氨基－α－(1－氮杂双环[2.2.2]辛－3－基)乙腈控释剂型 Download PDF

Info

Publication number
CN1235544A
CN1235544A CN97199411A CN97199411A CN1235544A CN 1235544 A CN1235544 A CN 1235544A CN 97199411 A CN97199411 A CN 97199411A CN 97199411 A CN97199411 A CN 97199411A CN 1235544 A CN1235544 A CN 1235544A
Authority
CN
China
Prior art keywords
dosage form
controlled release
compounds
polymer coating
package
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97199411A
Other languages
English (en)
Chinese (zh)
Inventor
S·M·米洛索维奇
W·穆尔多恩
J·A·纳珀
L·罗瑟奥
J·肖尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of CN1235544A publication Critical patent/CN1235544A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN97199411A 1996-09-12 1997-09-08 盐酸[R－(Z)]－α－甲氧亚氨基－α－(1－氮杂双环[2.2.2]辛－3－基)乙腈控释剂型 Pending CN1235544A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
GB9619074.9 1996-09-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN03102977A Division CN1446535A (zh) 1996-09-12 2003-01-23 盐酸[R－(Z)]－α－甲氧亚氨基－α－(1－氮杂双环[2.2.2]辛－3－基)乙腈控释剂型

Publications (1)

Publication Number Publication Date
CN1235544A true CN1235544A (zh) 1999-11-17

Family

ID=10799833

Family Applications (2)

Application Number Title Priority Date Filing Date
CN97199411A Pending CN1235544A (zh) 1996-09-12 1997-09-08 盐酸[R－(Z)]－α－甲氧亚氨基－α－(1－氮杂双环[2.2.2]辛－3－基)乙腈控释剂型
CN03102977A Pending CN1446535A (zh) 1996-09-12 2003-01-23 盐酸[R－(Z)]－α－甲氧亚氨基－α－(1－氮杂双环[2.2.2]辛－3－基)乙腈控释剂型

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN03102977A Pending CN1446535A (zh) 1996-09-12 2003-01-23 盐酸[R－(Z)]－α－甲氧亚氨基－α－(1－氮杂双环[2.2.2]辛－3－基)乙腈控释剂型

Country Status (22)

Country Link
EP (1) EP0929301A2 (enExample)
JP (1) JP2001500150A (enExample)
KR (1) KR20000036039A (enExample)
CN (2) CN1235544A (enExample)
AR (1) AR008176A1 (enExample)
AU (1) AU724086B2 (enExample)
BR (1) BR9711734A (enExample)
CA (1) CA2265661A1 (enExample)
CO (1) CO5031291A1 (enExample)
CZ (1) CZ83299A3 (enExample)
GB (1) GB9619074D0 (enExample)
HU (1) HUP9904401A3 (enExample)
ID (1) ID19589A (enExample)
IL (1) IL128781A0 (enExample)
MA (1) MA24359A1 (enExample)
NO (1) NO991194D0 (enExample)
NZ (1) NZ334268A (enExample)
PE (1) PE2499A1 (enExample)
PL (1) PL332074A1 (enExample)
TR (1) TR199900505T2 (enExample)
WO (1) WO1998010762A2 (enExample)
ZA (1) ZA978133B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100563648C (zh) 2003-04-25 2009-12-02 田边三菱制药株式会社 包含亚烷基二氧苯衍生物的口服组合物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
US6451343B1 (en) * 1998-03-11 2002-09-17 Smithkline Beecham Corporation Composition for treating dementia and Alzheimer's disease
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US20070009596A1 (en) * 2003-05-14 2007-01-11 Bruschi Stefano D L Controlled drug release composition resistant to in vivo mechanic stress
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
ME01316B (me) 2004-08-13 2013-12-20 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koji sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
UA88477C2 (ru) 2004-08-13 2009-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US20220211650A1 (en) * 2019-04-19 2022-07-07 Hoffman Technologies Llc Sustained release formulations
WO2026013563A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026013573A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026013570A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026013566A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026018154A1 (en) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinations of sabcomeline with non-cns penetrant muscarinic antagonists
WO2026018155A1 (en) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinations of sabcomeline with long-acting non-cns penetrant muscarinic antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE269330T1 (de) * 1989-04-13 2004-07-15 Beecham Group Plc Chemische verbindungen
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100563648C (zh) 2003-04-25 2009-12-02 田边三菱制药株式会社 包含亚烷基二氧苯衍生物的口服组合物

Also Published As

Publication number Publication date
CA2265661A1 (en) 1998-03-19
CZ83299A3 (cs) 1999-08-11
NZ334268A (en) 2000-10-27
CO5031291A1 (es) 2001-04-27
GB9619074D0 (en) 1996-10-23
TR199900505T2 (enExample) 1999-06-21
NO991194L (no) 1999-03-11
PL332074A1 (en) 1999-08-30
AU4128897A (en) 1998-04-02
WO1998010762A3 (en) 1998-06-04
NO991194D0 (no) 1999-03-11
PE2499A1 (es) 1999-03-24
HUP9904401A3 (en) 2001-03-28
ID19589A (id) 1998-07-23
BR9711734A (pt) 1999-08-24
MA24359A1 (fr) 1998-07-01
EP0929301A2 (en) 1999-07-21
CN1446535A (zh) 2003-10-08
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
ZA978133B (en) 1999-04-12
KR20000036039A (ko) 2000-06-26
JP2001500150A (ja) 2001-01-09
AR008176A1 (es) 1999-12-09
WO1998010762A2 (en) 1998-03-19
AU724086B2 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
CN1223341C (zh) 球形体、其制备方法以及药物组合物
CN1446535A (zh) 盐酸[R－(Z)]－α－甲氧亚氨基－α－(1－氮杂双环[2.2.2]辛－3－基)乙腈控释剂型
CN1117567C (zh) 帕罗西汀控释组合物
CN100341493C (zh) 用于延时和受控释放药物活性成分的微粒口服盖仑制剂
CN1202815C (zh) 含有曲马朵糖精盐的持续释放给药剂型
CN1227002C (zh) 包含聚醋酸乙烯酯和聚乙烯基吡咯烷酮的含活性成分漂浮形式及其用途与制备
CN1211086C (zh) 雷诺嗪持续释放制剂
CN1170540C (zh) 茶碱缓释片
CN1298317C (zh) 坦洛新片剂
CN1146410C (zh) 控制释放制剂
CN1976682A (zh) 用于延时和控制释放药物活性成分的微粒口服盖仑制剂
CN1033007A (zh) 持效性制剂
CN1489455A (zh) 延释药物制剂
CN1874767A (zh) 包含aplindore和其衍生物的缓释药物组合物
CN1747723A (zh) 含活性成分混合物的组合物及其制备方法
CN1993112A (zh) 用于具有高度pH依赖性溶解度的活性成分的控释的药物多层片剂
CN1662237A (zh) 控释医药组合物
CN1095665C (zh) 改性释放2－甲基－5－硝基－1－咪唑基－乙醇组合物及其制备和使用方法
CN1589156A (zh) 含有对酸不稳定的生理活性化合物的制剂组合物及其制法
CN1713896A (zh) 球形体、其制备方法以及药物组合物
CN1883459A (zh) 恩替卡韦的肠溶制剂及其制备方法
CN1682719A (zh) 一种含有石杉碱甲的肠溶包衣缓释片剂及制备方法
CN1286844C (zh) 含有血管紧张素ⅱ受体拮抗剂和b族维生素的药物组合物
CN1905880A (zh) 包含有机化合物的组合物
CN1571660A (zh) 用于哌嗪脲衍生物的固体药物制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication